This study evaluates the validity of an intravascular continuous glucose monitoring microdialysis probe, and compares the values to routinely inserted cerebral glucose microdialysis to evaluate the hypothesised relationship between intracranial and intravascular glucose levels.
All recruited patients will in any case have probes inserted in theatre for brain tissue glucose monitoring as a part of their standard clinical care. Probes will be allowed to stabilize following insertion as is standard clinical practice. A peripheral venous catheter will be inserted by the study team to allow introduction of the intravascular microdialysis probe. This will be attached to a regular infusion pump set at 3ml/hr and normal saline, to produce the microdialysate. The efflux of microdialysate will be connected to the biosensor, and once passed over the biosensor the subsequent dialysate will be destroyed. A risk assessment will be made on the basis of the patient's coagulation status and concurrent venous thromboembolism prophylaxis, and if necessary, low dose low molecular weight heparin will be included in the saline infusion to ameliorate risk of local thrombosis in the device. This has a local effect only and does not produce systemic anticoagulation.
After a brief period of probe stabilisation, 2 ml of blood will be withdrawn for blood gas analysis (including glucose), and the probe readings will be calibrated against this value. Subsequent calibration will take place 6 hours later, and then at 12 hourly intervals. A maximum total of 30ml of blood will be required for each patient for blood oxygen content analysis. Clinically necessitated blood sampling for blood gases will continue, and these values will be collected post-hoc from our E-hospital clinical records system.
Further data will be collected post-hoc via e-Hospital clinical records system, including: routinely recorded measures of cerebral extracellular fluid glucose concentration, physiological parameters (central venous pressure, mean arterial pressure, intracranial pressure etc), timing and detail of interventions as determined appropriate by routine clinical decision making.
The study will terminate at 72 hours, whereupon the device will be detached and the peripheral venous catheter will be removed.
- Ischemic Stroke
- Intracerebral Hemorrhage
- Subarachnoid Hemorrhage
- Traumatic Brain Injury
- Acquired Brain Injury
- MicroEye & ContinuMon Device
Intervention Desc: Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter. ARM 1: Kind: Experimental Label: Monitoring with MicroEye & ContinuMon Description: 72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
Patients who are admitted to the Neurocritical Care Unit with a severe acquired brain injury
|Type||Measure||Time Frame||Safety Issue|
|Primary||Continuously measured intravascular glucose concentration||72 hours|
|Secondary||Intermittently measured intravascular glucose concentration||72 hours|
|Secondary||Cerebral extracellular fluid glucose concentration||72 hours|